

TB in children; experiences from a low to middle income country, Papua New Guinea




Gordon Pukai

Paediatric Society of Papua New Guinea PATH, PMGH/UPNG- SMHS



Papua New Guinea (PNG)


- Situated in the south western Pacific and directly north of Australia
- Largest country in the Pacific with a population of almost 9 million people
- Known for its rugged mountainous terrains and it's vast scattered islands
- Known for it's variety of cultures and it's biological diversity
- A land of different tribes with well over 800 different native languages
- Set backs with our delivery of health services in view of difficult geographical terrains and different cultural beliefs and language barriers
- Common language- PNG 'Tok pisin'




TB in PNG

- TB incidence: 432/100,000 (7th worldwide)
 - ~30,000 cases/year
 - 26% of total reported TB cases occur in children (highest worldwide)

The majority of children diagnosed with MDR reflect that of adults. Most are currently in Daru and Port Moresby, but are reported throughout PNG



PNG TB Case Notification Trend: 2017-2022



 An CNR increase of 19% in 2022 from an average increase of 6-7% over the 5 years. Slides courtesy of NTP/WHO

Paediatric Ward at Port Moresby General Hospital (PMGH)

- 150 paediatric beds / 3,000 admissions
 - TB is the 3rd leading cause of admission (~13% of all admissions)
- 900 children started on TB treatment yearly (outpatient + inpatient)
 - 450 admitted
 - 10% in-hospital mortality for children diagnosed with TB if admitted
 - Present with severe disease,
 - 7% with HIV (new/CLHIV)
 - 40% with moderate/severe malnutrition



Q1 (Jan-March 2023) Top 10 Admissions at PMGH (Adults)




Table 1. DESCRIPTION OF 444 CHILDREN STARTED ON DSTBTREATMENT AT PMGH IN THE FIRST 6 MONTHS OF 2023

Indicator		Description	Total (n=444)	%	
Treatment site/ Catchment		PMGH TB Clinic	92	21%	
area		Other (BMU outside of PMGH)	er (BMU outside of PMGH) 352		
		NCD	239	54%	
Province or Origin		Central Province	105	24%	
		Other/Unknown	20	5%	
Inpatient vs Outpatient diagnosis (N=389)		Inpatient diagnosis	210	47%	
		Outpatient diagnosis	179	40%	
		Moderate malnutrition	59	13%	
Presence of malnutrition (n=347)		Severe malnutrition	93	21%	
		Overall (Mod + severe) 152		34%	
Xpert testing comple	eted	Yes	271	61%	
Xpert testing results		MTB detected: RR not detected - 73/444		16%	
Xpert testing results those tested (n=252	0	MTB detected; RR not detected – among children who received xpert testing	73/271	27%	

Registration of TB Patients

PMGH serves as an entry point for TB diagnosis and initiation of treatment

Children are started on treatment and then discharged for registration at local BM

Goal is to register >80% of children diagnosed with TB

Figure 4. Rates of HIV testing for children diagnosed with TB at PMGH




Table 1. X-pert testing and results for children diagnosed with DSTB at PMGH

DSTB	2019	2018	2019	2020	2021	2022
TB cases diagnosed and started on treatment at PMGH	810	588	1077	702	876	912
# children receiving Xpert testing	25	241	709	402	597	518
% of children receiving Xpert testing	3%	41%	66%	57%	68%	57%
<i># of cases bacteriologically confirmed by Xpert</i>	0	5	283	101	132	169
% of cases bacteriologically confirmed overall	0%	0.85%	283/1077 26%	101/702 14%	132/876 15%	169/912 19%
% of cases bacteriologically confirmed <u>among children tested</u>	0	2%	283/709 40%	101/402 25%	132/517 22%	169/518 33%

*2016 represents 5 months of data collection

The true confirmation rate is somewhere in between the "Confirmed Overall" and "Confirmed among children tested"

Drug resistant TB in PNG

PNG- Estimates of MDR-TB among TB

- Among new TB cases: 4%
- Among previously treated TB cases: 23%
- Estimates of MDR/RR-TB Incidence: 24/100,000 population
- Estimated new MDR-TB cases for 2021 was 2,400 of which only 535 (22%) were detected.
- Estimated MDR/RR-TB treatment coverage in 2021 is 22%: The global average is 36% coverage

DR-TB Treatment outcome rates

100% 1% 3% 3% 2% 3% 6% 9% 13% 9% 15% 90% 15% 18% 15% 5% 25% 15% 2% 36% 1% 80% 0% 17% 12% 5% 2% 14% 11% 14% 2% 70% 1% 11% 8% 13% Treatment outcome in % 11% 60% 12% 50% 40% 71% 69% 68% 67% 63% 63% 61% 30% 52% 20% 10% 0% 2015 2016 2017 2018 2019 2020 2021 2022 2023 Year

Treatment outcome of RR/MDR-TB

■ Treatment success rate ■ Death rate ■ Failure rate ■ LTFU rate ■ Not Evaluated rate

Slides courtesy of PNG NTP & WHO

Treatment outcomes for children with DRTB in PMGH

DRTB	2016	2017	2018	2019	2020	2021	2022	1H23	TOTAL
DRTB cases	13	19	33	21	39	29	35	14	214*
Treatment completed	9 (69%)	15 (78%)	25 (76%)	21 (100%)	27 (70%)	22 (75%)	30 (86%)		
Died	2 (15%)	3 (16%)	6 (18%)	0	6 (15%)	7 (24%)	5 (12%)		

*Total = 214 cases since 2014 and 2015 (data not shown for those years)

Current Regimens for DRTB in PNG

Pediatric regimens:

(i) 6 BDQ-Lfx-Lzd-Cfz/12 Lfx-Lzd-Cfz (longer all-oral regimen)

(ii) Adults: will introduce BPaL next year



International Union Against Tuberculosis and Lung Disease Health solutions for the poor

+

VOL 9 SUPPLEMENT 1 PUBLISHED 21 SEPTEMBER 2019

PNG SUPPLEMENT


Drug-resistant tuberculosis diagnosis since Xpert® MTB/RIF introduction in Papua New Guinea, 2012–2017

E. K. Lavu,¹ K. Johnson,^{1,2} J. Banamu,¹ S. Pandey,³ R. Carter,³ C. Coulter,³ P. Aia,⁴ S. S. Majumdar,⁵ B. J.


Table 2 Genotypic susceptibility of *Mycobacterium tuberculosis* strains in NCD, Daru, and other PNG provinces

WHO Group	Anti-TB drug	% NCD strains susceptible (n $=$ 66)	% Daru strains susceptible (n $=$ 100)
Group A	Levofloxacin OR moxifloxacin	95	88
	Bedaquiline	98	100
	Linezolid	100	100
Group B	Clofazimine	98	100
,	Cycloserine OR terizidone	100	100
Group C	Ethambutol	52*	44*
	Delamanid	100	100
	Pyrazinamide	61*	43*
	Imipenem-cilastatin OR meropenem, with clavulanic acid	Unknown	
	Amikacin	98	98
	Streptomycin	36	12
	Ethionamide OR prothionamide	38*	14*
	Para-aminosalicylic acid	98	100
_	High dose Isoniazid	27*	33*

NCD National Canital District PNG Panua New Guinea TR Tuberculosis



Practical guidance



Management of Multidrug-Resistant Tuberculosis in Children: A FIELD GUIDE

Fifth Edition, March 2022 Slides courtesy of Steve Graham and Ben Marais

Snapshot of DR-TB children at PMGH

- 2014-2023 = 214 DRTB case (started on treatment)
- Confirmed bacteriologically (X-pert) = 160/214 (75%)
- Cultures sent = 128/214 (60%)
 - Culture positive 40/128 (30%)
 - Only 31/128 (24%) with DST results
- MDR contact identified overall = 70/214 (32%)
- Previously treated for TB = 93/214 (43%)

- No prior TB treatment history = 121/214 (56%)
 - 51/121 (42%) Had an MDR contact
 - 70/121 (58%) No MDR contact, No prior treatment history
 - 66/70 (95%) were X-pert confirmed RR
- HIV positive = 8/200 (4%)
- MAM/SAM = 39/168 (23%)



Preventive therapy for child MDR contacts





TB Reach Grant "TB Free PNG"

Maternal Newborn
 Child Health (MNCH)
 TB Program

 Family-centered TB detection and linkage to care for peri-natal women

Introduction of radiology access to Maternity unity



20,000-30,000 screening CXR/year for TB at PMGH

Al software

- 1. MinXray at maternity
- 2. Main hospital
- 3. TBC (containerized xray)





TB Free PNG

- Scale up TB screening and diagnosis of pregnant and post-partum mothers
 - 77 moms with DSTB diagnosed, (1 MDR)
 - over last 4 months
 - Screen family members at home
 - Connection to community treatment supporters (NTP/WVI)
 - Introduction of CAD/AI software to PMGH (including pregnant women) expected 4Q23



TB Potts diagnosed in pregnant woman

Acknowledgements

- Outside contributors: Steve Graham, Shahidul Islam, Ben Marais, Jennifer Furin, Anna Mandalakas, Christoph Lange, Anca Vasiliu,
- Baylor College of Medicine Global Tuberculosis Program
- PNG Australia Transition to Health (PATH)
- Australia Department of Foreign Affairs and Trade (DFAT)
- The Paediatric Society of Papua New Guinea (PSPNG)
- The Port Moresby General Hospital (PMGH)



Tenk yu tru!